389 related articles for article (PubMed ID: 23897635)
1. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
[TBL] [Abstract][Full Text] [Related]
2. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
4. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
[TBL] [Abstract][Full Text] [Related]
5. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
[TBL] [Abstract][Full Text] [Related]
6. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.
Alan S; Erdeve O; Cakir U; Akduman H; Zenciroglu A; Akcakus M; Tunc T; Gokmen Z; Ates C; Atasay B; Arsan S;
J Matern Fetal Neonatal Med; 2016; 29(13):2186-93. PubMed ID: 26365531
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
[TBL] [Abstract][Full Text] [Related]
8. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
[TBL] [Abstract][Full Text] [Related]
9. Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.
O'Connell K; Boo TW; Keady D; Niriain U; O'Donovan D; Commane M; Faherty C; Cormican M
J Hosp Infect; 2011 Apr; 77(4):338-42. PubMed ID: 21330007
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
11. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.
Dizdar EA; Aydemir C; Erdeve O; Sari FN; Oguz S; Uras N; Dilmen U
J Hosp Infect; 2010 Aug; 75(4):292-4. PubMed ID: 20299133
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
16. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
17. Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.
Lee JH; Kim CS; Chang YS; Choi JH;
J Korean Med Sci; 2015 Oct; 30 Suppl 1(Suppl 1):S104-10. PubMed ID: 26566351
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
19. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit.
Halasa NB; Williams JV; Wilson GJ; Walsh WF; Schaffner W; Wright PF
Pediatr Infect Dis J; 2005 Dec; 24(12):1040-4. PubMed ID: 16371862
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab use in very premature infants in the neonatal intensive care unit.
Wu SY; Bonaparte J; Pyati S
Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
